European Society for Medical Oncology (ESMO)

Tweet this page
<
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 07 Nov 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

400,000€ - 499,999€

Financial year: May 2023 - Apr 2024

Lobbyists (Full time equivalent)

3.75 Fte (6)

Lobbyists with EP accreditation

3

High-level Commission meetings

4

Lobbying Costs over the years

  • Info

    European Society for Medical Oncology (ESMO)   (ESMO)

    EU Transparency Register

    947929324977-41 First registered on 08 Dec 2016

    Goals / Remit

    ESMO is the European Society for Medical Oncology. Representing more than 40,000 oncology professionals in 177 countries, ESMO is a reference for oncology education and information. ESMO’s core mission is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. It is to educate - doctors, patients with cancer and the general public - on the best practices and latest advances in oncology. And it is to promote equal access to optimal cancer care for all patients.

    Main EU files targeted

    EU policy fields of interest for ESMO include Health, Cancer, Chronic Diseases, Public Health, Research and Innovation, Cross Border Health Care, Health Technology Assessment, Data Protection, Clinical Trials, Digitalisation, EU's pharmaceutical Legislation, Orphan and Paediatric Medicines, Rare Diseases, Patients' Rights, Occupational Health, Environment/Air Quality, Medical Workforce.

    Address

    Head Office
    Via Ginevra 4
    Lugano 6900
    SWITZERLAND
    EU Office
    Via Ginevra 4
    Lugano 6900
    SWITZERLAND

    Website

    http://esmo.org

  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    100%2
    75%1
    50%1
    25%2

    Lobbyists (Full time equivalent)

    3.75

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    3 accreditations were / are live (in bold) for the selected state of 25 Nov 2024

    Name Start date End Date
    Agata KUSIAK 31 Jul 2024 31 Jul 2025
    Marijn SCHOLTE 31 Jul 2024 31 Jul 2025
    Agata KUSIAK 17 Feb 2024 04 Oct 2024
    Tanya KENNY 07 Mar 2024 04 Oct 2024
    Paul James LAFFIN 22 Feb 2024 04 Oct 2024
    Marijn SCHOLTE 14 Dec 2023 12 Sep 2024
    Robert Delis 10 Apr 2024 10 Apr 2026
    Robert Delis 18 Apr 2023 26 Apr 2024
    Paul James LAFFIN 19 Oct 2022 19 Oct 2023
    Ms Daniela Morghenti 15 Oct 2022 14 Oct 2023
    Marijn SCHOLTE 06 Oct 2022 05 Oct 2023
    Ms Fiona GREENHALGH 20 Feb 2020 01 Mar 2021
    Ms Anna CARTA 07 Nov 2019 07 Nov 2020
    Ms Emilie Hoogland 12 Mar 2019 01 Apr 2020
    Malvika VYAS 06 Mar 2019 29 Feb 2020
    Ms Anna CARTA 22 Sep 2018 01 Oct 2019
    Mr Paolo Casali 14 Apr 2018 13 Apr 2019
    Malvika VYAS 02 Mar 2018 02 Mar 2019
    Ms MONICA GHEORGHE 31 Aug 2017 31 Aug 2018
    Malvika VYAS 23 Jan 2017 19 Jan 2018
    Ms Aurélie Paviza 23 Jan 2017 31 Aug 2017
    Mr Paolo Casali 23 Jan 2017 19 Jan 2018

    Complementary Information

    The above percentages are estimates and vary dependent upon internal prioritization.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Trade unions and professional associations

  • Networking

    Affiliation

    ESMO is a full member of the Union of International Cancer Control (UICC, Geneva) and the European Medicines Agency's (EMA) Healthcare Professionals Working Party. ESMO is an associate member of the NCD Alliance. ESMO has 'Official Relations Status' with the World Health Organization (WHO), and 'Special Consultative Status' with the United Nations Economic and Social Council (ECOSOC). ESMO also participates in the COMBINE Project, the Critical Medicines Alliance (CMA), and the European Medicines Agency Cancer Medicines Forum (EMA CMF)

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    May 2023 - Apr 2024

    Lobbying costs for closed financial year

    400,000€ - 499,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    400,000€ - 499,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    ESMO engages frequently with the 3 main institutions of the EU - the European Commission, Parliament and Council - concerning the development of EU policies relevant for the medical oncology space. The Society - on an ongoing basis - shares its views on EU legislative proposals and processes through individual meetings with EU officials, position statements, social media campaigns, recommended amendments to EU legislation, and letters setting out the position of the Society.

    Other activities

    None declared

  • Meetings

    Meetings

    4 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

Download this datacard